Takeda San Diego, Inc.

Evotec to Collaborate with Takeda Cambridge for Multi-target Hit Identification

Evotec AG  announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.Evotec will apply its state-of-the-art Screening Platform and proprietary GPCR ... more

Approval of Additional Indication of NESINA: Combination Therapy with Thiazolidinediones for Type 2 Diabetes in Japan

Takeda Pharmaceutical Company Limited announced that an additional indication for “NESINA®” (generic name: Alogliptin), combination therapy with thiazolidinediones for type 2 diabetes, was approved by the Japanese Ministry of Health, Labour and Welfare. NESINA, a dipeptidyl peptidase-IV ( ... more

Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin for Treatment of Type 2 Diabetes

Takeda Pharmaceutical Company Limited and Takeda Global Research & Development Center, Inc., a wholly owned United States subsidiary, jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascu ... more

Takeda San Diego, Inc.

Takeda San Diego (TSD) is Takeda's global center for excellence in structure-based drug discovery. TSD integrates cutting-edge protein crystallography and drug discovery technologies to efficiently generate Investigational New Drug (IND) candidates for the treatment of metabolic diseases an ... more